BioCardia Returns to Full Compliance with Nasdaq Listing Requirements

SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (Nasdaq: BCDA), a global leader in cellular and cell-derived therapies for the treatment of cardiovascular and pulmonary diseases, today announced that the Company has returned to full compliance with the listing requirements of the Nasdaq Capital Market, as required by the decision of its Hearing Panel (the “Panel”) on May 13, 2024.

On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) of the Nasdaq Stock Market. Accordingly, the Panel determined to continue the listing of the Company’s securities on the Nasdaq Stock Market and closed this case.